Table 1.
Cohort characteristics.
| Elite controllers | Viremic progressors | Healthy controls | p-Value | |
|---|---|---|---|---|
| n | 19 | 32 | 23 | |
| Age in years, median (IQR) | 46 (40–52) | 39 (32–52) | 45 (39–52) | 0.36a |
| Male, n (%) | 10 (53) | 15 (47) | 13 (57) | 0.77a |
| Ethnicity, n (%) | ||||
| Caucasian | 8 (42) | 20 (63) | 18 (78) | 0.19 |
| Black | 10 (53) | 11 (34) | 4 (17) | |
| Other | 1 (5) | 1 (3) | 1 (4) | |
| Mode of transmission, n (%) | ||||
| Heterosexual | 10 (53) | 23 (72) | NA | 0.11 |
| MSM | 4 (22) | 8 (25) | ||
| PWID | 2 (10) | 0 | ||
| Blood product | 2 (10) | 0 | ||
| Unknown | 1 (5) | 1 (3) | ||
| Time since diagnosis, years- median (IQR) | 9.0 (5.0–14.0) | 1.3 (0.1–3.6) | NA | < 0.001b |
| CD4 count, cells/mm3, median (IQR) | 950 (695–1160) | 410 (302–527) | NA | < 0.001b |
| CD8 count, cells/mm3, median (IQR) | 670 (570–900) | 975 (735–1215) | NA | 0.005b |
| CD4/CD8 ratio | 1.52 (0.82–1.74) | 0.46 (0.29–0.57) | NA | < 0.001b |
| Viral load, Log10 copies/mL, median (IQR) | < 1.27 | 4.60 (3.85–5.03) | NA | < 0.001b |
| HIV-1 subtype, n (%) | ||||
| A1 | 0 | 6 (19) | NA | 0.001 |
| B | 3 (16) | 11 (34) | ||
| C | 5 (26) | 5 (16) | ||
| Recombinant forms | 2 (11) | 10 (31) | ||
| Unknown | 9 (47) | 0 |
NA: Not available, IQR: Interquartile range, MSM: Men who sex with men, PWID: People who inject drugs.
a
The Kruskal–Wallis test.
b
Mann-Whitney U test.